• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Natera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/18/25 4:01:44 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    false 0001604821 0001604821 2025-06-12 2025-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 12, 2025

     

     

     

    Natera, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-37478   01-0894487

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    13011 McCallen Pass
    Building A, Suite 100

    Austin, TX 78753

    (Address of principal executive offices, including zip code)

     

    (650) 980-9190

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $0.0001 per share   NTRA  

    Nasdaq Stock Market LLC

    (Nasdaq Global Select Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

     

    Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    As described below, on June 12, 2025, Natera, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Amended and Restated 2015 Equity Incentive Plan (the “Amended and Restated 2015 Plan”). The Amendment increases the shares reserved for issuance under the Amended and Restated 2015 Plan by 3.6 million shares of the Company’s common stock,.

     

    The Company’s officers and directors are among the persons eligible to receive awards under the Amended and Restated 2015 Plan in accordance with the terms and conditions thereunder. A detailed summary of the Amendment is set forth in Proposal No. 4 in the Company’s Definitive Proxy Statement on Schedule 14A for the Annual Meeting (the “Proxy Statement”), which was filed with the U.S. Securities and Exchange Commission on April 24, 2025. Such detailed summary of the Amendment and the foregoing description of the Amendment are qualified in their entirety by reference to the full text of the Amended and Restated 2015 Plan and the forms thereunder, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

     

    Item 5.07.Submission of Matters to a Vote of Security Holders.

     

    On June 12, 2025, at the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more detail in the Proxy Statement.

     

    Only stockholders of record as of the close of business on April 15, 2025, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 135,952,062 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The holders of a total of 117,454,679 shares of common stock were present at the Annual Meeting, either in person or by proxy, which constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting. In deciding all matters at the Annual Meeting, each holder of the Company’s common stock was entitled to one vote for each share of common stock held as of the close of business on the record date.

     

    The tabulation of the stockholders’ votes on each proposal brought before the Annual Meeting is as follows:

     

    Proposal 1: The election of three directors to serve as Class I directors until the 2028 annual meeting of stockholders or until his or her successor is duly elected and qualified:

     

    Name  For  Withheld  Broker Non-Votes
    Roy Baynes  91,013,565  21,534,462  4,906,652
    Gail Marcus  79,701,229  32,846,798  4,906,652
    Ruth Williams-Brinkley  109,000,744  3,547,283  4,906,652

     

    Proposal 2: The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025:

     

    For  Against  Abstentions  Broker Non-Votes
    116,762,105  662,144  30,430  0

     

    Proposal 3: The advisory vote on the compensation of the Company’s named executive officers:

     

    For  Against  Abstentions  Broker Non-Votes
    107,796,630  4,604,390  147,007  4,906,652

     

    Proposal 4: The approval of an amendment to the Amended and Restated 2015 Equity Incentive Plan:

     

    For  Against  Abstentions  Broker Non-Votes
    83,347,717  29,141,954  58,356  4,906,652

     

     

     

     

    Item 9.01.Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Amended and Restated 2015 Equity Incentive Plan, as amended.
    104   Cover Page Interactive Data File (formatted as inline XBRL).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Natera, Inc.
         
      By: /s/ Michael Brophy
        Michael Brophy
        Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

     

    Dated: June 18, 2025

     

     

    Get the next $NTRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    12/2/2025$265.00Overweight
    Morgan Stanley
    10/27/2025$172.00Underperform → Neutral
    BNP Paribas Exane
    9/22/2025$175.00Equal Weight
    Wells Fargo
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    2/20/2024$68.00 → $85.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CO-FOUNDER Sheena Jonathan exercised 4,436 shares at a strike of $9.29, increasing direct ownership by 2% to 227,096 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    12/11/25 8:35:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Director Chapman Rowan E exercised 4,000 shares at a strike of $32.15 and sold $1,061,389 worth of shares (4,366 units at $243.10), decreasing direct ownership by 6% to 5,777 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    12/9/25 8:35:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel exercised 6,902 shares at a strike of $19.68, increasing direct ownership by 3% to 208,601 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    12/8/25 9:55:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

    Multicenter, Signatera™ Genome-guided interventional trial will evaluate different treatment approaches in HR+/HER2- breast cancer Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study, which is a multicenter, phase II clinical trial in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Breast cancer is the most common cancer in women worldwide, with approximately 2.3 million new cases diagnosed in 2022.1 Despite advances in treatment, recurrence remains a key concern for patients with

    12/12/25 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

    MRD status after surgery stratifies patients beyond established clinical and genomic risk tools Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG), today announced initial translational research results from the international randomized Phase III PALLAS study. Presented today at the San Antonio Breast Cancer Symposium (SABCS), these first data, generated from a U.S. biomarker cohort of 420 patients, show that molecular residual disease (MRD) status, measured by the Signatera Genome test after surgery (and adjuvant chemotherapy +/- radiatio

    12/10/25 7:57:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

    Real-world Signatera™ analysis and Foresight CLARITY™ results from the HOVON study demonstrate the value of personalized ctDNA testing in therapy response assessment and surveillance Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today shared the results from two oral presentations that were presented at the American Society of Hematology (ASH) Annual Meeting. Real-world Signatera Analysis: Oral Presentation on December 6 A real-world analysis of personalized circulating tumor DNA (ctDNA) detection in lymphoma evaluated 144 patients across 14 lymphoma subtypes, including aggressive and indolent lymphomas and patients undergoing chimeric antigen recep

    12/9/25 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Natera with a new price target

    Morgan Stanley resumed coverage of Natera with a rating of Overweight and set a new price target of $265.00

    12/2/25 8:28:19 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Natera from Underperform to Neutral and set a new price target of $172.00

    10/27/25 9:03:32 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Wells Fargo resumed coverage on Natera with a new price target

    Wells Fargo resumed coverage of Natera with a rating of Equal Weight and set a new price target of $175.00

    9/22/25 8:32:15 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    SEC Filings

    View All

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    12/12/25 10:07:26 AM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form S-3ASR filed by Natera Inc.

    S-3ASR - Natera, Inc. (0001604821) (Filer)

    12/10/25 9:02:55 AM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form RW filed by Natera Inc.

    RW - Natera, Inc. (0001604821) (Filer)

    12/10/25 9:00:03 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Financials

    Live finance-specific insights

    View All

    Natera Acquires Foresight Diagnostics

    Expands Natera's lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera's portfolio of >500 issued or pending patents Accelerates Natera's expansion into lymphoma, where Foresight has developed a strong clinical position Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight. Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company's ci

    12/5/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Reports Third Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period. Generated a gross margin percentage2 of 64.9% in the third quarter of 2025, compared to a gross margin percentage2 of 61.8% in the third quarter of 2024. Processed approximately 893,600 tests in the third quarter of 2025, compared to approximately 775,800 tests in the third quarter of 2024,

    11/6/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Report its Third Quarter Results on November 6, 2025

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET. Earnings Conference Call Information Event: Natera's Third Quarter 2025 Financial Results Date: November 6, 2025 Time: 4:30 p.m. ET Live Dial-In: 1-888-770-7321 (Domestic)   1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/822764987

    10/30/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

    Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

    6/5/23 11:06:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

    Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

    2/23/23 8:05:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

    AUSTIN, Texas, May 24, 2022  /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg

    5/24/22 8:03:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    6/7/24 12:07:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care